A pharmacist framework for implementation of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain.
作者信息
Murphy Laura, Chang Feng, Dattani Shelita, Sproule Beth
机构信息
Department of Pharmacy (Murphy), Toronto Rehab, University Health Network, Toronto.
School of Pharmacy (Chang), University of Waterloo, Waterloo.
出版信息
Can Pharm J (Ott). 2019 Jan 3;152(1):35-44. doi: 10.1177/1715163518818200. eCollection 2019 Jan-Feb.
Abstract
摘要
相似文献
1
A pharmacist framework for implementation of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain.一个用于实施《加拿大慢性非癌性疼痛阿片类药物指南》的药剂师框架。
Can Pharm J (Ott). 2019 Jan 3;152(1):35-44. doi: 10.1177/1715163518818200. eCollection 2019 Jan-Feb.
2
Attitudes toward the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain: A qualitative study.对《加拿大慢性非癌性疼痛安全有效使用阿片类药物指南》的态度：一项定性研究。
J Opioid Manag. 2016 Nov/Dec;12(6):377-387. doi: 10.5055/jom.2016.0357.
3
Perceptions and Impact of the 2017 Canadian Guideline for Opioid Therapy and Chronic Noncancer Pain: A Cross-Sectional Study of Canadian Physicians.《2017年加拿大阿片类药物治疗与慢性非癌性疼痛指南》的认知与影响：一项针对加拿大医生的横断面研究
Pain Res Manag. 2020 Feb 17;2020:8380171. doi: 10.1155/2020/8380171. eCollection 2020.
4
Knowledge and implementation of current opioids guideline among healthcare providers in Manitoba.曼尼托巴省医疗保健提供者对当前阿片类药物指南的了解与实施情况。
J Opioid Manag. 2019 Jan/Feb;15(1):27-34. doi: 10.5055/jom.2019.0483.
5
Impact of Pharmacist Previsit Input to Providers on Chronic Opioid Prescribing Safety.药师预访对医疗提供者开具慢性阿片类药物处方安全性的影响。
J Am Board Fam Med. 2018 Jan-Feb;31(1):105-112. doi: 10.3122/jabfm.2018.01.170210.
6
Announcing the CDC guideline for prescribing opioids for chronic pain.宣布美国疾病控制与预防中心关于慢性疼痛开具阿片类药物的指南。
J Safety Res. 2016 Jun;57:83-4. doi: 10.1016/j.jsr.2016.03.007. Epub 2016 Apr 16.
7
Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain.《2017年加拿大慢性非癌性疼痛阿片类药物指南》中的不一致之处。
CMAJ. 2017 Oct 2;189(39):E1233. doi: 10.1503/cmaj.733244.
8
CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.美国 2016 年慢性疼痛阿片类药物处方指南。
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.
9
The authors respond to "Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain".作者们对《2017年加拿大慢性非癌性疼痛阿片类药物指南中的不一致之处》做出回应。
CMAJ. 2017 Oct 2;189(39):E1234-E1235. doi: 10.1503/cmaj.733313.
10
The use of oral opioids in patients with chronic non-cancer pain. Management strategies.慢性非癌性疼痛患者口服阿片类药物的使用。管理策略。
Med J Aust. 1997 Jul 7;167(1):30-4.
引用本文的文献
1
The standards of practice for delivery of polypharmacy and chronic disease medication reviews by general practice clinical pharmacists: a consensus study.全科临床药师提供复方用药和慢性病药物治疗审核的实践标准：一项共识研究。
Int J Clin Pharm. 2022 Jun;44(3):663-672. doi: 10.1007/s11096-022-01387-7. Epub 2022 Mar 23.
2
Pharmacists' perceptions of the Canadian opioid regulatory exemptions on patient care and opioid stewardship.药剂师对加拿大阿片类药物监管豁免对患者护理及阿片类药物管理的看法。
Can Pharm J (Ott). 2021 Aug 16;154(6):394-403. doi: 10.1177/17151635211034530. eCollection 2021 Nov-Dec.
3
The Impact of a Primary Care, Pharmacist-Driven Intervention in Patients with Chronic Non-Cancer Pain-A Pilot Study.一项针对慢性非癌性疼痛患者的由初级保健药师主导的干预措施的影响——一项试点研究
Pharmacy (Basel). 2020 Jul 8;8(3):113. doi: 10.3390/pharmacy8030113.
4
Impact of pharmacist-led medication assessments on opioid utilization.药剂师主导的药物评估对阿片类药物使用的影响。
Can Pharm J (Ott). 2020 Mar 13;153(3):148-152. doi: 10.1177/1715163520908285. eCollection 2020 May-Jun.
本文引用的文献
1
Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada.处方和非处方阿片类药物对阿片类药物相关死亡的影响：加拿大安大略省基于人群的队列研究
BMJ. 2018 Aug 29;362:k3207. doi: 10.1136/bmj.k3207.
2
Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study.比较加拿大各地处方阿片类药物对阿片类药物相关住院治疗的贡献：一项多司法管辖区的横断面研究。
Drug Alcohol Depend. 2018 Oct 1;191:86-90. doi: 10.1016/j.drugalcdep.2018.06.028. Epub 2018 Jul 31.
3
Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions.慢性疼痛背景下阿片类药物减量指南：证据、实用建议及常见问题
Can Pharm J (Ott). 2018 Feb 8;151(2):114-120. doi: 10.1177/1715163518754918. eCollection 2018 Mar-Apr.
4
Pharmacists as accessible primary health care providers: Review of the evidence.药剂师作为可及的初级卫生保健提供者：证据综述
Can Pharm J (Ott). 2018 Jan 2;151(1):4-5. doi: 10.1177/1715163517745517. eCollection 2018 Jan-Feb.
5
Guideline for opioid therapy and chronic noncancer pain.阿片类药物治疗与慢性非癌性疼痛指南。
CMAJ. 2017 May 8;189(18):E659-E666. doi: 10.1503/cmaj.170363.
6
Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later.加拿大非医疗处方阿片类药物使用、与处方阿片类药物相关的危害及公共卫生：五年后的最新情况
Can J Public Health. 2014 Apr 16;105(2):e146-9. doi: 10.17269/cjph.105.4143.
7
The opioid manager: a point-of-care tool to facilitate the use of the Canadian Opioid Guideline.阿片类药物管理工具：一种便于使用《加拿大阿片类药物指南》的床边即时工具。
J Opioid Manag. 2012 Jan-Feb;8(1):57-61. doi: 10.5055/jom.2012.0097.
8
Opioid dose and drug-related mortality in patients with nonmalignant pain.非恶性疼痛患者的阿片类药物剂量与药物相关死亡率
Arch Intern Med. 2011 Apr 11;171(7):686-91. doi: 10.1001/archinternmed.2011.117.
9
Opioid therapy for chronic pain.用于慢性疼痛的阿片类药物治疗。
N Engl J Med. 2003 Nov 13;349(20):1943-53. doi: 10.1056/NEJMra025411.
Zotero 插件